Thomas D Gootz

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi Acinetobacter baumannii: an emerging multidrug-resistant threat
    Thomas D Gootz
    Department of Infectious Disease, Pfizer Global Research and Development, MS 220 2301, Eastern Point Road, Groton, CT 06340, USA
    Expert Rev Anti Infect Ther 6:309-25. 2008
  2. ncbi The forgotten Gram-negative bacilli: what genetic determinants are telling us about the spread of antibiotic resistance
    Thomas D Gootz
    Pfizer Global Research and Development, Department of Antibiotics, Immunology and Cancer, MS 220 2301, Eastern Point Road, Groton, CT 06340, USA
    Biochem Pharmacol 71:1073-84. 2006
  3. ncbi Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital
    Thomas D Gootz
    Department of Infectious Diseases, Pfizer Global Research and Development, Groton, CT 06340, USA
    Antimicrob Agents Chemother 53:1998-2004. 2009
  4. ncbi Bacterial efflux pump inhibitors
    Barbara J Kamicker
    Pfizer Global R and D, MS, Groton, CT, USA
    Methods Mol Med 142:187-204. 2008
  5. ncbi High-level carbapenem resistance in a Klebsiella pneumoniae clinical isolate is due to the combination of bla(ACT-1) beta-lactamase production, porin OmpK35/36 insertional inactivation, and down-regulation of the phosphate transport porin phoe
    Frank M Kaczmarek
    Pfizer Global Research and Development, Groton, CT 06340, USA
    Antimicrob Agents Chemother 50:3396-406. 2006
  6. ncbi Enterococcal virulence determinants may be involved in resistance to clinical therapy
    Andrea Marra
    Pfizer Global Research and Development, Groton, CT 06340, USA
    Diagn Microbiol Infect Dis 58:59-65. 2007
  7. ncbi Global dissemination of beta-lactamases mediating resistance to cephalosporins and carbapenems
    Thomas D Gootz
    Pfizer Global Research and Development, Department of Antimicrobials, Immunology and Cancer, Eastern Point Road, Groton, Connecticut 06340, USA
    Expert Rev Anti Infect Ther 2:317-27. 2004
  8. ncbi Genetic and molecular characterization of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae with unusually high resistance to ampicillin
    Frank S Kaczmarek
    Department of Immunology and Infectious Disease, Pfizer Global Research and Development, Groton, Connecticut 06340, USA
    Antimicrob Agents Chemother 48:1630-9. 2004
  9. ncbi Minimum inhibitory concentrations of tulathromycin against respiratory bacterial pathogens isolated from clinical cases in European cattle and swine and variability arising from changes in in vitro methodology
    Kevin S Godinho
    Veterinary Medicine Research and Development, Pfizer Ltd, Sandwich, Kent, UK
    Vet Ther 6:113-21. 2005
  10. ncbi The current state of antibacterial research
    Thomas D Gootz
    Expert Rev Anti Infect Ther 1:1-3. 2003

Collaborators

  • Wenchi Shang
  • Andrea Marra
  • Michael T Sweeney
  • Anthony J Milici
  • Fadia Dib-Hajj
  • Barbara J Kamicker
  • Frank M Kaczmarek
  • Kevin S Godinho
  • Frank S Kaczmarek
  • Kim Crimin
  • Joan Duignan
  • Frank Kaczmarek
  • M Anne Jones
  • Andrew J Weatherley
  • Hafid A Benchaoui
  • Ian A Nanjiani
  • Simon J Sunderland
  • Sue G Keane
  • Tim G Rowan
  • Melissa Cronan
  • Shawn Hallowell

Detail Information

Publications10

  1. ncbi Acinetobacter baumannii: an emerging multidrug-resistant threat
    Thomas D Gootz
    Department of Infectious Disease, Pfizer Global Research and Development, MS 220 2301, Eastern Point Road, Groton, CT 06340, USA
    Expert Rev Anti Infect Ther 6:309-25. 2008
    ....
  2. ncbi The forgotten Gram-negative bacilli: what genetic determinants are telling us about the spread of antibiotic resistance
    Thomas D Gootz
    Pfizer Global Research and Development, Department of Antibiotics, Immunology and Cancer, MS 220 2301, Eastern Point Road, Groton, CT 06340, USA
    Biochem Pharmacol 71:1073-84. 2006
    ....
  3. ncbi Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital
    Thomas D Gootz
    Department of Infectious Diseases, Pfizer Global Research and Development, Groton, CT 06340, USA
    Antimicrob Agents Chemother 53:1998-2004. 2009
    ..This study increases our understanding of the genetic composition of the evolving and expanding role of KPC-producing, healthcare-associated, gram-negative pathogens...
  4. ncbi Bacterial efflux pump inhibitors
    Barbara J Kamicker
    Pfizer Global R and D, MS, Groton, CT, USA
    Methods Mol Med 142:187-204. 2008
    ..In whole bacterial cells synergism antagonism or indifference of the combination of an antibiotic with the putative inhibitor is determined and this is then confirmed by quantitating viable bacterial cells in liquid culture over 24 h...
  5. ncbi High-level carbapenem resistance in a Klebsiella pneumoniae clinical isolate is due to the combination of bla(ACT-1) beta-lactamase production, porin OmpK35/36 insertional inactivation, and down-regulation of the phosphate transport porin phoe
    Frank M Kaczmarek
    Pfizer Global Research and Development, Groton, CT 06340, USA
    Antimicrob Agents Chemother 50:3396-406. 2006
    ..Our results with this pair of Klebsiella clinical isolates highlight the complex and evolving nature of multiple drug resistance in this species...
  6. ncbi Enterococcal virulence determinants may be involved in resistance to clinical therapy
    Andrea Marra
    Pfizer Global Research and Development, Groton, CT 06340, USA
    Diagn Microbiol Infect Dis 58:59-65. 2007
    ..These results suggest that although there may not be an absolute role for individual virulence determinants in infectivity, combinations of factors may play a role in allowing a biofilm infection to be more resistant to therapy...
  7. ncbi Global dissemination of beta-lactamases mediating resistance to cephalosporins and carbapenems
    Thomas D Gootz
    Pfizer Global Research and Development, Department of Antimicrobials, Immunology and Cancer, Eastern Point Road, Groton, Connecticut 06340, USA
    Expert Rev Anti Infect Ther 2:317-27. 2004
    ..Continued reviews of the literature are necessary in order to keep abreast of the ingenuity with which bacteria are changing the current genetic landscape to confer resistance to this important class of antimicrobials...
  8. ncbi Genetic and molecular characterization of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae with unusually high resistance to ampicillin
    Frank S Kaczmarek
    Department of Immunology and Infectious Disease, Pfizer Global Research and Development, Groton, Connecticut 06340, USA
    Antimicrob Agents Chemother 48:1630-9. 2004
    ..67 micro g/ml, typical for BLNAR strains. These studies illustrate that BLNAR strains with high ampicillin MICs exist that have combined resistance mechanisms in PBP3 and in the AcrAB efflux pump...
  9. ncbi Minimum inhibitory concentrations of tulathromycin against respiratory bacterial pathogens isolated from clinical cases in European cattle and swine and variability arising from changes in in vitro methodology
    Kevin S Godinho
    Veterinary Medicine Research and Development, Pfizer Ltd, Sandwich, Kent, UK
    Vet Ther 6:113-21. 2005
    ..Isolates were retested in the presence of serum. The activity of tulathromycin against fastidious organisms was affected by culture conditions, and MICs were reduced in the presence of serum...
  10. ncbi The current state of antibacterial research
    Thomas D Gootz
    Expert Rev Anti Infect Ther 1:1-3. 2003